Enterprise Value
5.103B
Cash
1.313B
Avg Qtr Burn
N/A
Short % of Float
2.59%
Insider Ownership
2.42%
Institutional Own.
92.26%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CABOMETYX (cabozantinib) Details Solid tumor/s, Renal cell carcinoma, Cancer | Approved Quarterly sales | |
COTELLIC (cobimetinib) Details Metastatic melanoma | Approved Quarterly sales | |
COMETRIQ (cabozantinib) Details Metastatic MTC (Medullary Thyroid Cancer) | Approved Quarterly sales | |
CABOMETYX (cabozantinib)+atezolizumab Details Solid tumor/s, Cancer, Castration-resistant prostate cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Zanzalintinib (XL092) Details Solid tumor/s, Colorectal cancer , Cancer | Phase 3 Interim Update | |
Cabozantinib + Nivolumab + Ipilimumab Details Solid tumor/s, Cancer, Kidney cancer | Phase 3 Update | |
Zanzalintinib (XL092) Details Solid tumor/s, Colorectal cancer , Cancer | Phase 1b Interim update | |
CBX-12 (topoisomerase I inhibition) Details Solid tumor/s, Cancer | Phase 1 Update |